Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;9(5):345-52.
doi: 10.1007/s11910-009-0051-4.

Update on amyloid imaging: from healthy aging to Alzheimer's disease

Affiliations
Review

Update on amyloid imaging: from healthy aging to Alzheimer's disease

David A Wolk et al. Curr Neurol Neurosci Rep. 2009 Sep.

Abstract

We report on the current state of in vivo amyloid imaging. Although this technique is less than a decade old, a wealth of information is emerging as the initial clinical studies are being reported. Imaging of patients with Alzheimer's disease has allowed quantitative exploration of the natural history of amyloid deposition and its relationship to neurodegeneration. Amyloid imaging also shows significant promise in the differential diagnosis of mild cognitive impairment or atypical dementias. However, amyloid detection may be of greatest utility in healthy elderly persons; consistent with prior autopsy studies, a significant proportion of asymptomatic individuals display increased levels of amyloid by in vivo imaging. Understanding the relationship between this pathology and future cognitive status has significant implications for the application of disease-modifying medications in the "preclinical" phase of disease. Given the considerable clinical experience compared with other tracers, this review focuses on the literature involving Pittsburgh compound B positron emission tomography.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PiB retention by region in healthy controls, patients with mild cognitive impairment, and patients with Alzheimer's disease. PiB distribution volume ratio (DVR) values based on 90 minutes of scanning with cerebellum as reference quantified for frontal cortex (FRC), precuneus (PRC), and subcortical white matter (SWM). The white bars represent University of Pittsburgh cut-off values for dichotomous determination of “amyloid-positive” versus “amyloid-negative” scans. Red triangles: healthy controls; black circles: mild cognitive impairment patients; blue squares: Alzheimer's disease patients.
Figure 2
Figure 2
Axial and mid-sagittal PiB PET images of amyloid-positive (NC+) and amyloid-negative (NC-) healthy controls and patients with mild cognitive impairment (MCI+ and MCI-, respectively) compared with a typical patient with Alzheimer's disease. Images are quantified by distribution volume ratio (DVR).

References

    1. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–63. - PubMed
    1. Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584–95. - PubMed
    1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19. - PubMed
    1. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15:869–77. xi–xii. - PMC - PubMed
    1. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598–606. - PMC - PubMed

Substances